Welcome to our dedicated page for Pulse Biosciences news (Ticker: $PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pulse Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pulse Biosciences's position in the market.
Pulse Biosciences, Inc. (PLSE) announced the first U.S. procedure using the CellFX nsPFA Percutaneous Electrode System after FDA clearance. The successful case marks a significant milestone in the company's pilot program, showing promising results in treating soft tissue without damaging noncellular structures. The innovative technology aims to revolutionize patient care with minimal pain and no need for general anesthesia. The company is looking forward to expanding the procedure's usage in 2024, following successful trials in Italy.
Pulse Biosciences, Inc. reported business updates and financial results for the first quarter of 2024, highlighting FDA clearance for CellFX nsPFA Percutaneous Electrode, ongoing dialogue with the FDA for CellFX nsPFA Cardiac Clamp, and submission of a feasibility study for CellFX nsPFA 360° Cardiac Catheter. Additionally, the company announced a planned rights offering of up to $60 million to fund growth plans, with a change in record date. Financially, GAAP costs and expenses increased driven by non-cash stock-based compensation, resulting in a net loss of ($10.1) million for Q1 2024. Cash and cash equivalents totaled $34.9 million as of March 31, 2024.
Pulse Biosciences, Inc. (PLSE) announced a rights offering for up to $60 million, with a record date set for May 16, 2024. The offering allows common stockholders to purchase Units at $10 or the market price. Each Unit includes one share of common stock and two warrants. The offering includes an over-subscription right. The Registration Statement with the SEC has been filed but is not yet effective.